Precision Health Clinical Trials

Genetic Testing for Men With Metastatic Prostate Cancer

Conditions:   Metastatic Prostate Carcinoma;   Stage IV Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8
Interventions:   Procedure: Biospecimen Collection;   Other: Genetic Counseling;   Other: Genetic Testing;   Other: Laboratory Biomarker Analysis;   Behavioral: Questionnaire
Sponsors:   University of Washington;   National Cancer Institute (NCI)
Recruiting

A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC

Conditions:   Malignant Hydrothorax;   NSCLC
Intervention:   Diagnostic Test: in vitro NGS-panel
Sponsors:   Shanghai Chest Hospital;   Sinotech Genomics Co., Ltd;   Amoy Diagnostics Co., LTD;   Guangzhou Burning Rock Medical Examination Institute Co., Ltd.;   Geneplus-Beijing Co. Ltd.;   Berry Genomics Co., Ltd.
Recruiting

Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies

Conditions:   Sarcoma;   Endocrine Tumors;   Neuroblastoma;   Retinoblastoma;   Renal Cancer
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Recruiting

ctDNA as a Biomarker for Treatment Response in HNSCC

Condition:   Carcinoma, Squamous Cell of Head and Neck
Intervention:   Other: Blood draw
Sponsor:   The Netherlands Cancer Institute
Not yet recruiting

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Condition:   Metastatic Hormone-Sensitive Prostate Cancer
Interventions:   Biological: PROSTVAC-V;   Biological: PROSTVAC-F;   Drug: Nivolumab;   Drug: Ipilimumab;   Biological: Neoantigen DNA vaccine;   Device: TriGrid Delivery System;   Procedure: Tumor biopsy;   Procedure: Peripheral blood;   Procedure: Fecal samples
Sponsors:   Washington University School of Medicine;   Bristol-Myers Squibb
Not yet recruiting

Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status

Conditions:   Colorectal Neoplasms;   Microsatellite Instability
Interventions:   Drug: temozolomide (induction),;   Biological: pembrolizumab (treatment)
Sponsor:   IFOM, The FIRC Institute of Molecular Oncology
Not yet recruiting

Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety

Condition:   Growth and Development
Intervention:  
Sponsor:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Conditions:   Advanced Malignant Solid Neoplasm;   ALK Fusion Protein Expression;   ALK Gene Mutation;   ALK Gene Translocation;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Histiocytosis;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   ROS1 Fusion Positive;   ROS1 Gene Mutation;   ROS1 Gene Translocation
Interventions:   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
Sponsor:   National Cancer Institute (NCI)
Recruiting

Two Cancers, One Gene. Why Some People in Families Develop Melanoma or Pancreas Cancer, While Still Others Never Develop Cancer.

Conditions:   Pancreas Cancer;   Melanoma
Intervention:  
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting

The Epigenetic Modification in OPRM1 on Postoperative Analgesia and Side Effect Induced by Sufentanil

Condition:   Epigenetics
Interventions:   Drug: Sufentanil;   Drug: dexmedetomidine;   Drug: propofol;   Drug: Rocuronium;   Drug: sevoflurane;   Drug: remifentanil;   Drug: Parecoxib
Sponsor:   Huazhong University of Science and Technology
Recruiting

Pages